Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 1, 2016

Ergomed and Asarina to jointly conduct Phase IIb trial of Sepranolone to treat premenstrual dysphoric disorder

Clinical trial services and drug development company Ergomed has entered a co-development agreement with Asarina Pharma to conduct the Phase IIb clinical trial of Sepranolone (UC1010) to treat premenstrual dysphoric disorder (PMDD).

Clinical trial services and drug development company Ergomed has entered a co-development agreement with Asarina Pharma to conduct the Phase IIb clinical trial of Sepranolone (UC1010) to treat premenstrual dysphoric disorder (PMDD).

PMDD is characterised by cyclic symptoms such as depression, anxiety, irritability, mood lability and loss of emotional control consistently at the latter part of the menstrual cycle, affecting a woman's personal and professional life.

The disorder is experienced during the fertile period beginning from menstruation until menopause.

Under the agreement, Ergomed will conduct Asarina’s multicentre, multinational, randomised Phase IIb clinical trial next year and will jointly invest into the trial in return for an equity stake in Asarina.

"Asarina’s proprietary Sepranolone is an endogenous, small molecule acting as a GABA-A modulating steroid antagonist (GAMSA)."

Ergomed CEO Dr Miroslav Reljanovic said: “We are delighted to be the co-development partner for Asarina as it embarks upon its Phase IIb clinical trial programme for Sepranolone, which has the potential to be a first-in-class therapy for this serious disease.

“This further expands the number of pipeline opportunities where we share in the potential upside as a drug is successfully developed through leveraging our expertise and experience in providing clinical trial services to support such development.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Asarina’s proprietary Sepranolone is an endogenous, small molecule acting as a GABA-A modulating steroid antagonist (GAMSA).

Sepranolone has demonstrated its safety, efficacy and pharmacokinetics profile in an exploratory, double-blind, randomised, placebo-controlled, clinical phase I/II study conducted by Asarina on 120 women with PMDD.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU